Advertisement
Canada markets open in 6 hours 9 minutes
  • S&P/TSX

    22,011.72
    +139.76 (+0.64%)
     
  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     
  • DOW

    38,503.69
    +263.71 (+0.69%)
     
  • CAD/USD

    0.7312
    -0.0009 (-0.12%)
     
  • CRUDE OIL

    83.45
    +0.09 (+0.11%)
     
  • Bitcoin CAD

    91,464.12
    +679.40 (+0.75%)
     
  • CMC Crypto 200

    1,416.79
    -7.31 (-0.51%)
     
  • GOLD FUTURES

    2,335.90
    -6.20 (-0.26%)
     
  • RUSSELL 2000

    2,002.64
    +35.17 (+1.79%)
     
  • 10-Yr Bond

    4.5980
    -0.0250 (-0.54%)
     
  • NASDAQ futures

    17,722.75
    +116.00 (+0.66%)
     
  • VOLATILITY

    15.69
    0.00 (0.00%)
     
  • FTSE

    8,077.52
    +32.71 (+0.41%)
     
  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     
  • CAD/EUR

    0.6836
    0.0000 (0.00%)
     

Can Teva’s Fremanezumab Revert Chronic Migraine to Episodic?

Can Teva’s Fremanezumab Revert Chronic Migraine to Episodic?

As we saw in the previous part of this series, Teva presented new data on fremanezumab at the AHS (American Headache Society) 60th Annual Scientific Meeting in San Francisco. It is one of Teva’s key pipeline drugs and is expected to be a key growth driver for the company. Teva’s specialty products pipeline is provided in the graph below.